VRTX financials
Vertex Pharmaceuticals Incorporated · end-of-day data as of Oct 16, 2026
Vertex Pharmaceuticals Incorporated
$499.74+4.7%
Buy · 33 analystsPT $569.95 +14.0%
VRTX reported revenue of $3.33B for the quarter ended Jun 30, 2026 (Q2 FY2026), up 12.5% from a year earlier. It posted diluted EPS of $4.31, free cash flow of $1.01B and a net margin of 33.0%.
Valuation
- P/E29.1x
- P/E vs own+3.3%
- P/E vs sector+3.3%
- FCF yield+3.0%
- Market cap$127B
Quarterly results
Q2 FY2026: Revenue +12.5% year over year, free cash flow 30.4% of revenue, operating margin 37.4%.
RevenueFree cash flow
| Q2 FY2026 | Jun 30, 2026 | $3.33B | 4.31 | $1.01B | 85.3% | 37.4% | 33.0% |
| Q1 FY2026 | Mar 31, 2026 | $2.99B | 4.02 | $1.29B | 86.8% | 38.1% | 34.5% |
| Q4 FY2025 | Dec 31, 2025 | $3.23B | 4.65 | $349M | 85.6% | 40.3% | 36.9% |
| Q3 FY2025 | Sep 30, 2025 | $3.08B | 4.20 | $1.14B | 86.5% | 38.6% | 35.2% |
| Q2 FY2025 | Jun 30, 2025 | $2.96B | 3.99 | $927M | 86.3% | 38.8% | 34.8% |
| Q1 FY2025 | Mar 31, 2025 | $2.77B | 2.49 | $778M | 86.9% | 22.7% | 23.3% |
| Q4 FY2024 | Dec 31, 2024 | $2.91B | 3.50 | $492M | 85.5% | 35.2% | 31.4% |
| Q3 FY2024 | Sep 30, 2024 | $2.77B | 4.01 | $1.3B | 85.8% | 40.3% | 37.7% |
| Q2 FY2024 | Jun 30, 2024 | $2.65B | -13.92 | -$3.83B | 85.9% | -132.9% | -135.8% |
| Q1 FY2024 | Mar 31, 2024 | $2.69B | 4.21 | $1.06B | 87.3% | 42.4% | 40.9% |
| Q4 FY2023 | Dec 31, 2023 | $2.52B | 3.71 | $177M | 85.4% | 39.3% | 38.5% |
| Q3 FY2023 | Sep 30, 2023 | $2.48B | 3.97 | $1.23B | 87.2% | 41.8% | 41.7% |